- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04640142
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
April 8, 2024 updated by: Octapharma
Prospective, Open-label, Single-arm, Multicentre Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
Study Overview
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patrick Murphy
- Phone Number: 866-337-1868
- Email: ctgov@clinicalresearchmgt.com
Study Locations
-
-
-
Leipzig, Germany, 04129
- Recruiting
- Octapharma Research Site
-
Munich, Germany, 80337
- Recruiting
- Octapharma Research Site
-
-
-
-
-
Budapest, Hungary, 1097
- Recruiting
- Octapharma Research Site
-
Debrecen, Hungary, 4032
- Recruiting
- Octapharma Research Site
-
-
-
-
-
Napoli, Italy, 80131
- Recruiting
- Octapharma Research Site
-
Roma, Italy, 133
- Not yet recruiting
- Octapharma Research Site
-
Roma, Italy, 00161
- Recruiting
- Octapharma Research Site
-
Roma, Italy, 133
- Recruiting
- Octapharma Research Site
-
Treviso, Italy, 31100
- Not yet recruiting
- Octapharma Research Site
-
-
-
-
-
Kraków, Poland, 30-663
- Recruiting
- Octapharma Research Site
-
Warsaw, Poland, 04-730
- Withdrawn
- Octapharma Research Site
-
-
-
-
-
Bratislava, Slovakia, 833 40
- Recruiting
- Octapharma Research Site
-
Martin, Slovakia, 036 59
- Withdrawn
- Octapharma Research Site
-
-
-
-
-
Kyiv, Ukraine, 04209
- Terminated
- Octapharma Research Site
-
Lviv, Ukraine, 79010
- Recruiting
- Octapharma Research Site
-
Lviv, Ukraine, 79035
- Recruiting
- Octapharma Research Site
-
-
-
-
California
-
Irvine, California, United States, 92697
- Recruiting
- Octapharma Research Site
-
Los Angeles, California, United States, 90024
- Recruiting
- Octapharma Research Site
-
-
Florida
-
Saint Petersburg, Florida, United States, 33701
- Recruiting
- Octapharma Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- Octapharma Research Site
-
-
Kansas
-
Overland Park, Kansas, United States, 66211
- Recruiting
- Octapharma Research Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- Recruiting
- Octapharma Research Site
-
-
Maryland
-
White Marsh, Maryland, United States, 21162
- Recruiting
- Octapharma Research Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Active, not recruiting
- Octapharma Research Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68046
- Recruiting
- Octapharma Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 75 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age of ≥2 years and ≤75 years
- Documented and confirmed diagnosis of PID as defined by European Society of Immunodeficiencies (ESID) and the Pan American Group for Immune Deficiency (PAGID) and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. The exact type of PID must be recorded.
- At least 12 weeks of regular treatment before the screening visit (i.e., with a stable dosing interval) with any IVIG, SCIG, or fSCIG, with a stable IgG dose between 200 and 800 mg/kg/month. A stable dose is defined as one that deviates less than ±25% from the mean dose for all infusions within this 12-week period before screening.
- Trough level of IgG ≥5 g/L at screening and documentation of an IgG trough level of ≥5 g/L at least once within the previous 12 weeks.
- Freely given written informed consent from adult patients or freely given written informed consent from the patient's parent(s)/legal guardian(s) and written informed assent from paediatric or adolescent patients in accordance with the applicable regulatory requirements, before any study-specific procedure takes place.
- Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
Exclusion Criteria:
- Any acute infection requiring IV antibiotic treatment within 2 weeks before the screening visit or during the screening period, or any SBI within the 3 months prior to the screening visit or during the screening period.
- The patient has isolated specific antibody deficiency disorder, isolated IgG subclass deficiency, or transient hypogammaglobulinaemia of infancy.
- Current medical condition or history of condition known to cause secondary immune deficiency, for example, chronic lymphocytic leukaemia, lymphoma, multiple myeloma, or chronic or recurrent neutropenia (absolute neutrophil count <1000/μL).
- Known history of ADRs to IgA contained in other products.
- Body mass index >40 kg/m2.
- Exposure to blood or any blood product or plasma derivative other than IgG for PID within 3 months before the first infusion of Newnorm.
- History of or ongoing severe hypersensitivity, e.g., anaphylaxis or severe systemic response, or persistent reactions to blood or plasma-derived products, or to any component of Newnorm (such as glycine).
- Severe liver dysfunction (alanine aminotransferase [ALT] >3 times the upper limit of normal for the expected normal range for the testing laboratory) at screening.
- Known protein-losing enteropathies or proteinuria (known urinary protein loss of >1 g/24 h, or dipstick proteinuria of ≥3+).
- Moderate to severe renal dysfunction (per investigator discretion based on estimated glomerular filtration rate [eGFR] ≤44 mL/min/1.73 m2, as defined by KDIGO Clinical Practice Guideline) or predisposition to acute renal failure (e.g., any degree of pre-existing renal dysfunction in presence of additional acute renal failure risk factors, e.g. routine treatment with known nephrotoxic drugs).
- Uncontrolled diabetes mellitus (HbA1c > 7% / >53 mmol/mol).
- Uncontrolled arterial hypertension (systolic blood pressure of ≥ 130 mmHg for the subject under 13 years of age, ≥ 140 mmHg for subject 13 to 17 years of age, and > 160 mmHg for adults).
- Dysrhythmia/Tachycardia (resting heart rate > 100 bpm for adults/adolescents and > 120 bpm for children) and symptomatic bradycardia (resting heart rate < 60 bpm for adults, < 50 bpm for adolescents, and < 75 bpm for children in presence of symptoms e.g., low blood pressure, abnormal rhythm, chest discomfort, shortness of breath). Physiological sinus bradycardia in physically active adults/children/athletes is NOT an exclusion criterion).
- The subject has a history of or current diagnosis of deep venous thrombosis or thromboembolism (e.g. myocardial infarction, cerebrovascular accident, or transient ischemic attack); history refers to an incident in the year prior to screening or 2 episodes over lifetime.
- The subject is currently receiving anti-coagulation therapy which would make SC administration inadvisable (vitamin K antagonist, nonvitamin K antagonist oral anticoagulants [e.g. dabigatran etexilate targeting Factor IIa, rivaroxaban, edoxaban, and apixaban targeting Factor Xa], parenteral anticoagulants [e.g. fondaparinux]).
Treatment with oral or parenteral steroids either
- at daily doses >0.3 mg/kg of prednisone (or equivalent) within the last 12 weeks before screening or
- bolus treatment of a daily dose greater than 1 mg/kg of prednisone (or equivalent) for longer than 10 days within the last 12 weeks before screening. Courses of corticosteroids (intermittent) of not more than 10 days would not exclude a patient. Inhaled or topical corticosteroids are allowed.
- Treatment with systemic immunosuppressants including chemotherapeutic agents 1 year before screening or immunomodulatory drugs 12 weeks before the screening visit.
- Live viral vaccination (such as measles, rubella, mumps, or varicella) within 1 month before the first infusion of Newnorm, during the study period, and within 3 months after last infusion of Newnorm. Note: Seasonal inactivated (killed) influenza vaccines (incl. H1N1) are allowed. COVID vaccines (mRNA vaccine and a non-replicating viral vector vaccine) are allowed.
- Treatment with any investigational medicinal product (IMP) within 3 months before the screening visit.
- Presence of any condition likely to interfere with the evaluation of Newnorm or with the compliant conduct of the study.
- Known or suspected abuse of alcohol, drugs, and/or psychotropic agents within 12 months before screening.
- Known human immunodeficiency virus (HIV)-1/2, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection or positive for HIV-1/2, HBV, or HCV at screening.
- Women who are breast feeding, pregnant, or planning to become pregnant, or are unwilling to use an effective birth control method (refer to protocol Section 7.4.10.b) while on study and for 30 days following the last dose of study drug.
- Men who are unwilling to use birth control to prevent pregnancy for the duration of the study (unless the female partner
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Newnorm
Newnorm is a 20% human normal immunoglobulin for SC infusion
|
Newnorm is a 20% human normal immunoglobulin for SC infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Serious Bacterial Infections
Time Frame: 52 weeks
|
Rate of SBIs (defined as bacteraemia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess) per person-year on treatment.
|
52 weeks
|
Average total IgG concentration
Time Frame: 16 weeks
|
Average total IgG concentration (Cav) on steadystate dosing.
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Infections of any type of seriousness
Time Frame: 52 weeks
|
Infections of any type or seriousness (including acute sinusitis, exacerbation of chronic sinusitis, acute otitis media, acute bronchitis, infectious diarrhoea, etc) (total and by category, annual rate)
|
52 weeks
|
Time to resolution of infections
Time Frame: 52 weeks
|
Time to resolution of infections
|
52 weeks
|
Use of antibiotics
Time Frame: 52 weeks
|
Use of antibiotics (number of days on antibiotics and annual rate of treatment episodes) characterised as therapeutic or prophylactic use
|
52 weeks
|
Hospitalisations due to infection
Time Frame: 52 weeks
|
Hospitalisations due to infection (number of days and annual rate)
|
52 weeks
|
Episodes of fever
Time Frame: 52 weeks
|
Episodes of fever
|
52 weeks
|
Days lost from work, school, kindergarten, or day care due to infection
Time Frame: 52 weeks
|
Days lost from work, school, kindergarten, or day care due to infection
|
52 weeks
|
Child Health Questionnaire-Parent Form
Time Frame: 52 weeks
|
Child Health Questionnaire-Parent Form (CHQPF50) for patients <14 years
|
52 weeks
|
SF-36 Health Survey
Time Frame: 52 weeks
|
SF-36 Health Survey for patients ≥ 14 of age
|
52 weeks
|
Non-compartmental PK analyses of all available PK profiles (IVIG and SCIG)
Time Frame: 16 weeks
|
Total IgG, IgG subclasses (IgG1, IgG2, IgG3, and IgG4), and antigen specific antibodies against Haemophilus influenzae B (capsular polysaccharide), Streptococcus pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), cytomegalovirus (CMV), tetanus, and measles
|
16 weeks
|
IgG Levels
Time Frame: 16 weeks
|
Trough and peak levels of total IgG and IgG subclasses for weekly Newnorm relative to 3- or 4-weekly IVIG dosing
|
16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 4, 2021
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
November 17, 2020
First Submitted That Met QC Criteria
November 17, 2020
First Posted (Actual)
November 23, 2020
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NORM-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Immune Deficiency
-
Caja Costarricense de Seguro SocialCompleted
-
University Hospital, CaenCompletedPrimary Immune Deficiency DisorderFrance
-
CSL LimitedCompletedPrimary Immune Deficiency (PID)Australia
-
Therapure Biopharma IncUnknownPrimary Immune Deficiency Diseases (PIDD)United States, Canada
-
OctapharmaCompleted
-
ADMA Biologics, Inc.CompletedPrimary Immune Deficiency Disorders (PIDD)United States
-
CSL BehringCompletedPrimary Immune Deficiency | Secondary Immune DeficiencyCanada
-
University Hospital, CaenCompleted
-
Instituto Grifols, S.A.CompletedPrimary Immune Deficiency DiseaseUnited States
-
Johns Hopkins All Children's HospitalRecruitingMetabolic Disease | Primary Immune Deficiency DisordersUnited States